论文部分内容阅读
The development of Drug Safety Monitoring Boards (DSMBs) in the US and European Countries was a result of the recognition that frequently safety issues for subjects in an approved clinical study were not being discovered or acted upon in a timely manner by the Sponsor of the Study (Pharma frequently but not exclusively).